Structure Therapeutics has its much-anticipated oral GLP-1 data, and the results look to give the next-generation contender a chance against market incumbents Eli Lilly and Novo Nordisk.

The biotech said Monday …

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, according to a research letter published online March 11 in JAMA Network Open.

As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment.

THURSDAY, March 12, 2026 — Less than 25 percent of adults with overweight or obesity without diabetes remain on any glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment after 12 months, according to a research letter published online March…

(MedPage Today) — Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday.
Following laboratory testing, the drugmaker said it uncovered…

THURSDAY, March 12, 2026 — Formulation- and sex-specific associations are seen for semaglutide use with ischemic optic neuropathy, with increased odds in men and with Wegovy use, according to a study published online March 10 in the British Journal…

Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could alter the drug’s toxicity profile and pose safety risks to patients, the company said in an open letter.

THURSDAY, March 12, 2026 — People frequently switch between different weight-loss drugs, swapping Ozempic for Zepbound and vice versa within the first year of treatment, a new study reports.
What’s more, those patients who do swap GLP-1…

(MedPage Today) — The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications.
In a letter dated March 5 and made public on Tuesday, the…

(MedPage Today) — GLP-1 receptor agonist use was associated with a lower risk of death in cancer patients with brain metastases and type 2 diabetes, a retrospective cohort study found.
Within 3 years of a first recorded brain metastasis, patients…

A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It’s a simple premise: What if something as small as a digital nudge could put someone on the path to healthier habits while taking GLP-1 medications?

The FDA has issued a warning letter to Novo Nordisk saying the maker of Ozempic and Wegovy failed to report potential side effects in patients who took the medications. The agency cited three deaths among patients, including one who died by suicide. The FDA says the company did not report the deaths within the agency’s required time and that it also failed to investigate or report the suicide.

Patients without diabetes who switched GLP-1 receptor agonist (GLP-1RA) drugs for overweight or obesity were more likely to stick with their treatment longer than those who didn’t switch, according to a new study by UT Southwestern Medical Center researchers. The findings, published in JAMA Network Open, suggest that medication changes are not uncommon among patients undergoing weight loss and that clinicians should encourage them to change GLP-1RAs if necessary to promote continuity of care.

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of “eye stroke” (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.

(MedPage Today) — The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed.
In a…

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescriptions increased from 2018 to 2025, while MBS use decreased beginning in 2023, according to a research letter published online March 4 in JAMA Surgery.

These kitchen staples are nutrient-dense and easy to tolerate.

(MedPage Today) — GLP-1 receptor agonists may increase the risk of bone and tendon injuries, as well as conditions like osteoporosis and gout, a retrospective study suggested. (Washington Post)
Chairside HbA1c testing during routine dental visits…

NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and…

Plainsboro, NJ, US and Bagsværd, Denmark, 09 March 2026 – Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that will take effect later this month. Under the terms of the agreement, Hims…

(MedPage Today) — Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see branded semaglutide (Ozempic, Wegovy) products sold through the…

(MedPage Today) — Note that some links may require registration or subscription.
GLP-1 receptor agonists may increase the risk of bone and tendon injuries along with conditions such as osteoporosis and gout, a retrospective study suggested. …

Some patients taking popular GLP-1 weight loss drugs may be able to keep the weight off while taking injections less often, according to a small new study.

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue. In the paper “Bimagrumab and semaglutide alone or in combination for the treatment of obesity: a phase 2 randomized clinical trial,” published Monday in the journal Nature Medicine, Dr. Steven Heymsfield of Pennington Biomedical Research Center describes the results of the BELIEVE study, which showed that the therapy combination addressed lean mass loss associated with GLP-1-based therapies.

(MedPage Today) — Initiation of a GLP-1 receptor agonist was tied to lower risks of several substance use disorders (SUDs) in adults with type 2 diabetes, according to a target trial emulation using data on veterans.
In patients without a history…

South San Francisco, CA — March 5, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493…

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, drinking and opioid use disorders and addiction.

A year after stopping taking weight-loss drugs such as Ozempic and Wegovy, people regain—on average—60% of their lost weight. But beyond this, their regained weight plateaus, with individuals managing to keep off 25% of the weight lost to treatment, say researchers at the University of Cambridge. The work appears in eClinicalMedicine.

Research led by Penn Dental’s Henry Daniell investigates the use of a lettuce-based, plant-encapsulated delivery platform as a new oral delivery of two GLP-1 drugs previously approved by the FDA in injectable form.

Popular GLP-1 receptor agonist drugs for weight loss, also known as GLP-1 RAs, appear to be similarly effective among patients of different ages, races, and starting weights, with women benefiting somewhat more than men, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1…

Plainsboro, NJ, US and Bagsværd, Denmark, February 24, 2026 –Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide)…

Could weight-loss drugs shrink the body representation we’ve spent decades seeking?

Here’s a summary of the major announcements and trends from the 44th Annual JP Morgan Healthcare Conference in San Francisco (January 12–15, 2026) specifically in

JP Morgan 2026: Obesity & GLP-1 Therapies Take Center StageWhat the Latest Deals and Data Mean for the Future of Metabolic MedicineThe J.P. Morgan Healthcare

Here are the **highlights from Day 2 of the JP Morgan Healthcare Conference (San Francisco) specifically related to obesity, weight-gain therapies, and related drug developments

JP Morgan Healthcare Conference – Day 3 Highlights (Obesity & Metabolic Therapies)1. Shift From “Weight Loss” to Chronic Metabolic DiseaseDay 3 discussions made it clear